Abstract
Intrathecal drug delivery systems (IDDS) have emerged as a valuable treatment option for patients with chronic pain who have failed to achieve adequate relief with conventional therapies. These systems provide targeted delivery of medications directly to the cerebrospinal fluid, resulting in improved pain control and reduced systemic side effects. However, the use of IDDS is not without potential complications and considerations that must be addressed to ensure optimal patient outcomes. This comprehensive review examines the various complications associated with IDDS and the considerations that healthcare providers and patients need to be aware of. Surgical complications, such as infection, bleeding, spinal fluid leaks, and nerve damage, are discussed, along with strategies to minimize these risks. Device malfunctions, including pump failure, catheter issues, and electronic problems, are explored, highlighting the importance of regular monitoring and maintenance. Medication-related side effects, such as nausea, sedation, and respiratory depression, are addressed, emphasizing the need for close monitoring and appropriate dosage adjustments. Long-term considerations, including tolerance to medication, physical dependence, and withdrawal symptoms, are also examined, emphasizing the significance of gradual tapering and proper discontinuation protocols. The review underscores the importance of regular follow-up appointments to assess the system's functionality, medication dosages, and patient response to treatment. By proactively managing and addressing complications, healthcare providers can optimize pain relief and minimize adverse effects, ensuring the long-term effectiveness and safety of IDDS.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmaceutical Science,Pharmacology
Reference82 articles.
1. Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M. The polyanalgesic consensus conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation. 2017;20(2):155-76. doi: 10.1111/ner.12579, PMID 28042914.
2. Kharkar S, Saffron BN, Krames E. Intrathecal therapy for cancer and nonmalignant pain. Neurotherapeutics. 2009;6(1):39-59.
3. Cohen SP, Hayek SM. Intrathecal drug delivery for pain. Curr Pain Headache Rep. 2016;20(6):34.
4. Brogan SE, Winter NB, Okifuji EA. Intrathecal drug delivery systems for refractory cancer pain. Curr Pain Headache Rep. 2014;18(1):390.
5. De Andres J, Grau J, Lopez Alarcon MD. Alpha-2 agonists for the treatment of chronic pain. J Pain Res. 2009;2:307-20.